BiotechTube

Relaxin + Placebo

Phase 2/3Completed
0 watching 0 views this week📈 Rising
65
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Heart Failure, Congestive

Conditions

Heart Failure, Congestive

Trial Timeline

Oct 1, 2007 → Sep 1, 2012

NCT ID
NCT00520806

About Relaxin + Placebo

Relaxin + Placebo is a phase 2/3 stage product being developed by Novartis for Heart Failure, Congestive. The current trial status is completed. This product is registered under clinical trial identifier NCT00520806. Target conditions include Heart Failure, Congestive.

Hype Score Breakdown

Clinical
22
Activity
15
Company
10
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT00520806Phase 2/3Completed

Competing Products

20 competing products in Heart Failure, Congestive

See all competitors
ProductCompanyStageHype Score
IV diureticNuwellisPre-clinical
15
IV Loop DiureticsNuwellisPre-clinical
15
Stepped pharmacologic careNuwellisPhase 3
69
IV Loop Diuretics (LD)NuwellisPre-clinical
15
TRV120027 + Normal SalineTrevenaPhase 1
25
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
44
TRV120027 + PlaceboTrevenaPhase 1/2
33
Ilofotase alfa + PlaceboAM-PharmaPhase 2
44
INXN-4001PrecigenPhase 1
28
LY3461767 + PlaceboEli LillyPhase 1
33
SGLT2i, beta blocker, ARNI, MRA, MTDEli LillyApproved
85
Pactimibe, CS-505Daiichi SankyoPhase 2
52
Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeksDaiichi SankyoApproved
85
olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetilDaiichi SankyoPhase 3
77
OlmesartanDaiichi SankyoPhase 3
77
Carperitide + PlaceboDaiichi SankyoPhase 2
52
EdoxabanDaiichi SankyoPre-clinical
23
RegadenosonAstellas PharmaPhase 1
33
Advagraf + PrografAstellas PharmaPhase 2
52
FK506EAstellas PharmaPhase 3
77

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85